06-21-00

A

APPLICATION FOR LETTER PATENT UNDER 37 CFR 1.51

* * * * *

Application of: Christopher Graham Raphael Parsons, Wojciech Danysz, Markus Gold, Ivars Kalvinsh, Valerjans Kauss, and Aigars Jirgensons

For: AMINO-ALKYLCYCLOHEXANES AS 5-HT_3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS

* * * * *

HON. COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

TRANSMITTAL LETTER UNDER 37 CFR 1.51

Sir:

Herewith please find the application above-identified, complete in accordance with 37 CFR 1.51, consisting of the following:

[X] Specification (31 pages Specification, 7 pages Claims) and 1 page Abstract

[X] Declaration/Power of Attorney

[X] Drawings - 4 sheets bearing FIGS. 1 through 4

[X] Filing fee of Seven hundred sixty-two Dollars ($762) with check no. 68648 for 2 independent and 22 dependent claims.

[X] Notice Re: Fees, in triplicate.

Respectfully submitted,

G O R D O N W. H U E S C H E N

Attorney

Dated: June 19, 2000
715 The "H" Building
310 East Michigan Avenue
Kalamazoo, MI 49007
616-382-0030

Enclosure: As above-identified
Return postal card receipt

06-2100

* * * * *

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

* * * * *

Case No. MERZ30/dln

Application for Letters Patent

Applicant(s): Christopher Graham Raphael Parsons, et al.
Title : AMINO-ALKYLCYCLOHEXANES AS 5-HT_3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

"Express Mail" No.: EL455869477US
Date of Deposit: June 20, 2000

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Diane L. Newton
Name of person mailing paper

Diane L. Newton
Signature

1-AMINO-ALKYLCYCLOHEXANES AS 5-HT_3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS

Field of Invention

New uses of 1-amino-alkylcyclohexanes.

Prior Art

The prior art is represented by our prior USP 6,034,134 of March 7, 2000 and our published application WO 99/01416, PCT/EP98/04026, and Parsons et al. Neuropharmacology 38, 85-108 (1999), wherein the active compounds utilized according to the present invention are disclosed and disclosed to be NMDA receptor antagonists and anticonvulsants.

The Present Invention

The present invention is directed to a new use of 1-amino-alkylcyclohexane compounds selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$
wherein n+m = 0, 1, or 2
wherein R^1 through R^7 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C), and wherein R^8 and R^9 each represent hydrogen or lower-alkyl (1-6C) or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and enantiomers, optical isomers, hydrates, and pharmaceutically-acceptable salts thereof, as well as pharmaceutical compositions thereof, and the preparation and use of such compounds and compositions as $5HT_3$ and neuronal nicotinic receptor antagonists and neuroprotective agents for the treatment of a living animal for the alleviation of conditions responsive thereto.

Representative of these compounds are as follows:
MRZ 2/579: 1-Amino-1,3,3,5,5-pentamethylcyclohexane, HCl
601: 1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane, HCl
607: 1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group), HCl
615: 1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers), HCl
616: 1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers), HCl
617: 1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers), HCl
618: 1-Amino-1,3 (trans),5 (trans)-trimethyl-3(cis)-propylcyclohexane, HCl
620: 1-Amino-1,3-dimethyl-3-ethylcyclohexane, HCl
621: 1-Amino-1,3,3-trimethylcyclohexane, HCl
625: 1-Amino-1,3 (trans)-dimethylcyclohexane, HCl
627: 1-Amino-1-methyl-3 (trans) propylcyclohexane, HCl
629: 1-Amino-1-methyl-3 (trans) ethylcyclohexane, HCl
632: 1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane, HCl

633: 1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane, HCl

640: N-methyl-1-Amino-1,3,3,5.5-pentamethylcyclohexane, HCl

641: 1-Amino-1-methylcyclohexane, HCl

642: N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane, HCl.H_2O

705: N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine, HCl

680: 1-amino-1,3(trans),5(trans)-trimethylcyclohexane, HCl

681: 1-amino-1,3(cis),5(cis)-trimethylcyclohexane, HCl.H_2O,

682: 1-amino-(1R,5S)trans-5-ethyl-1,3,3-trimethylcyclohexane, HCl

683: 1-amino-(1S,5S)cis-5-ethyl-1,3,3-trimethylcyclohexane, HCl.H_2O,

1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane HCl,

1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane HCl,

1-Amino-1-methyl-3(cis)-ethyl-cyclohexane HCl,

1-Amino-1-methyl-3(cis)-methyl-cyclohexane HCl,

1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane HCl, and

Also, 1-amino-1,3,3,5,5-pentamethylcyclohexane,

1-amino-1,5,5-trimethyl-3,3-diethylcyclohexane,

1-amino-1-ethyl-3,3,5,5-tetramethylcyclohexane,

N-ethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,

N-(1,3,5-trimethylcyclohexyl)pyrrolidine or piperidine,

N-[1,3(trans),5(trans)-trimethylcyclohexyl]pyrrolidine or piperidine,

N-[1,3(cis),5(cis)-trimethylcyclohexyl]pyrrolidine or piperidine,

N-(1,3,3,5-tetramethylcyclohexyl)pyrrolidine or piperidine,

N-(1,3,3,5,5-pentamethylcyclohexyl)pyrrolidine or piperidine,

N-(1,3,5,5-tetramethyl-3-ethylcyclohexyl)pyrrolidine or piperidine,
N-(1,5,5-trimethyl-3,3-diethylcyclohexyl)pyrrolidine or piperidine,
N-(1,3,3-trimethyl-cis-5-ethylcyclohexyl)pyrrolidine or piperidine,
N-[(1S,5S)cis-5-ethyl-1,3,3-trimethylcyclohexyl] pyrrolidine or piperidine,
N-(1,3,3-trimethyl-trans-5-ethylcyclohexyl)pyrrolidine or piperidine,
N-[(1R,5S)trans-5-ethyl-1,3,3-trimethylcyclohexyl] pyrrolidine or piperidine,
N-(1-ethyl-3,3,5,5-tetramethylcyclohexyl)pyrrolidine or piperidine, and
N-(1-propyl-3,3,5,5-tetramethylcyclohexyl)pyrrolidine or piperidine,
and optical isomers, enantiomers, and the hydrochloride, hydrobromide, hydrochloride hydrate, or other pharmaceutically-acceptable salts of any of the foregoing.

Of particular interest are compounds of the foregoing formula wherein at least R^1, R^4, and R^5 are lower-alkyl and those compounds wherein R^1 through R^5 are methyl, those wherein x is 4 or 5, and in particular the compound N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine, and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts thereof.

In our USP 6,034,134 of March 7, 2000, we disclosed compounds of the foregoing formula, pharmaceutical compositions thereof, and their use as NMDA-receptor antagonists and anticonvulsants. It has now been found that compounds of the foregoing formula and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts thereof, in addition to their NMDA antagonist and anticonvulsant properties, quite

unpredictably possess a high degree of $5HT_3$ and neuronal nicotinic receptor antagonism, making them useful in the treatment of diseases and conditions where blockade of these receptors is important.

SUMMARY OF THE INVENTION

What we therefore believe to be comprised by our present invention may be summarized, inter alia, in the following words:

A method-of-treating a living animal for inhibition of progression or alleviation of a condition which is alleviated by a $5HT_3$ or neuronal nicotinic receptor antagonist, comprising the step of administering to the said living animal an amount of a 1-aminoalkylcyclohexane compound selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$
wherein n+m = 0, 1, or 2
wherein R^1 through R^7 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C),
wherein R^8 and R^9 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C) or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, which is effective for the said purpose; such a

method wherein at least R^1, R^4, and R^5 are lower-alkyl; such a

method wherein R^1 through R^5 are methyl; such a

method wherein R^1 is ethyl; such a

method wherein R^2 is ethyl; such a

method wherein R^3 is ethyl; such a

method wherein R^4 is ethyl; such a

method wherein R^5 is ethyl; such a

method wherein R^5 is propyl; such a

method wherein R^6 or R^7 is methyl; such a

method wherein R^6 or R^7 is ethyl; such a

method wherein X is 4 or 5; such a

method wherein the condition treated or inhibited is selected from the group consisting of emesis, anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease, cerebella tremor, Parkinson's disease, Tourette's, pain, and appetite disorders; such a

method wherein the compound is selected from the group consisting of

1-Amino-1,3,3,5,5-pentamethylcyclohexane,

1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane,

1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group),

1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers),

1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers),

1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers),

1-Amino-1,3 (trans),5(trans)-trimethyl-3(cis)-propyl-cyclo-hexane,

1-Amino-1,3-dimethyl-3-ethylcyclohexane,

1-Amino-1,3,3-trimethylcyclohexane,

1-Amino-1,3(trans)-dimethylcyclohexane,

1-Amino-1-methyl-3 (trans) propylcyclohexane,
1-Amino-1-methyl-3 (trans) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane,
N-methyl-1-Amino-1,3,3,5.5-pentamethylcyclohexane,
1-Amino-1-methylcyclohexane,
N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane,
1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,
1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,
1-Amino-1-methyl-3(cis)-methyl-cyclohexane,
1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and
N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,
and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts of any of the foregoing; and such a

method wherein the compound is administered in the form of a pharmaceutical composition thereof comprising the compound in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.

Moreover, a use of a 1-aminoalkylcyclohexane selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein n+m = 0, 1, or 2

wherein R^1 through R^7 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C), wherein R^8 and R^9 are independently selected from the group consisting of hydrogen and lower-alkyl or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, in the manufacture of a medicament to treat a living animal for alleviation of a condition which is alleviated by a $5HT_3$ receptor antagonist; such a

use wherein at least R^1, R^4, and R^5 are lower-alkyl; such a

use wherein R^1 through R^5 are methyl; such a

use wherein x is 4 or 5; such a

use wherein the compound is selected from the group consisting of

1-Amino-1,3,3,5,5-pentamethylcyclohexane,

1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane,

1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group),

1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers),

1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers),

1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers),

1-Amino-1,3 (trans),5 (trans)-trimethyl-3(cis)-propylcyclohexane,

1-Amino-1,3-dimethyl-3-ethylcyclohexane,

1-Amino-1,3,3-trimethylcyclohexane,

1-Amino-1,3 (trans)-dimethylcyclohexane,

1-Amino-1-methyl-3 (trans) propylcyclohexane,

1-Amino-1-methyl-3 (trans) ethylcyclohexane,

1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane,

1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane,

N-methyl-1-Amino-1,3,3,5.5-pentamethylcyclohexane,
1-Amino-1-methylcyclohexane,
N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane,
1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,
1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,
1-Amino-1-methyl-3(cis)-methyl-cyclohexane,
1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and
N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,
and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts of any of the foregoing; and, finally, such a

use wherein the condition treated is selected from the group consisting of emesis, anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease, cerebella tremor, Parkinson's disease, Tourette's, pain, and appetite disorders.

THE PRESENT INVENTION IN DETAIL

Background and Pharmacology

5-HT_3 Receptor Antagonists

5-HT_3 receptors are ligand gated ionotropic receptors permeable for cations. In man 5-HT_3 receptors show the highest density on enterochromaffin cells in the gastrointestinal mucosa, which are innervated by vagal afferents and the area postrema of the brain stem, which forms the chemoreceptor trigger zone.

Since 5-HT_3 receptors not only have a high density in the area postrema but also in the hippocampal and amygdala region of the limbic system, it has been suggested that 5-HT_3 selective antagonists may have psychotropic effects (Greenshaw & Silverstone, 1997).

Indeed, early animal studies suggested that the 5-HT_3 receptor antagonists, in addition to their well recognized anti-emetic use, may well be clinically useful in a number of areas. These include anxiety disorders, schizophrenia, drug and alcohol abuse disorders,

depressive disorders, cognitive disorders, Alzheimer's disease, cerebella tremor, Parkinson's disease treatment-related psychosis, pain (migraine and irritable bowel syndrome), and appetite disorders.

Neuronal nicotinic receptors

At present nine α subunits (α1-α9) and four ß (ß1-ß4) subunits for nicotinic are known. α4ß2 receptors are probably the most common in the CNS, especially in the hippocampus and striatum. They form non-selective cation channels with slowly, incompletely desensitizing currents (type II). Homomeric α7 receptors are both pre- and postsynaptic and are found in the hippocampus, motor cortex and limbic system as well as in the peripheral autonomic nervous system. These receptors are characterized by their high Ca^{2+} permeability and fast, strongly desensitizing responses (type 1A).

Changes in nicotinic receptors have been implicated in a number of diseases. These include Alzheimer's disease, Parkinson's disease, Tourette's, schizophrenia, drug abuse, and pain.

Based on the observation that the nicotinic agonist nicotine itself seems to have beneficial effects, drug development so far aimed at the discovery of selective nicotinic agonists.

On the other hand, it is unclear whether the effects of nicotinic agonists in, e.g., Tourette's syndrome and schizophrenia, are due to activation or inactivation / desensitization of neuronal nicotinic receptors.

The effects of agonists on neuronal nicotinic receptors is strongly dependent on the exposure period. Rapid reversible desensitization occurs in milliseconds, rundown occurs in seconds, irreversible inactivation of

α4ß2 and α7 containing receptors occurs in hours and their upregulation occurs within days.

In other words: the effects of nicotinic "agonists" may in fact be due to partial agonism, inactivation and/or desensitization of neuronal nicotinic receptors. In turn, moderate concentrations of neuronal nicotinic receptor channel blockers could produce the same effects as reported for nicotinic agonists in the above mentioned indications.

Amino-alkylcyclohexanes are 5-HT3 and neuronal nicotinic receptor antagonists

We speculated whether novel amino-alkylcyclohexane derivatives (USP 6,034,134), being there described as uncompetitive NMDA receptor antagonists and anticonvulsants, might possibly also act as 5HT3 and neuronal nicotinic antagonists. These properties would allow the use of the amino-alkylcyclohexanes in all diseases or conditions where blockade of 5HT3 or nicotinic receptors is important. Our findings were positive.

METHODS

Synthesis

The synthesis of the novel amino-alkylcyclohexanes which are utilized according to the present invention has been described in USP 6,034,134 of March 7, 2000.

Alternative Procedure

The 1-cyclic amino compounds may also be prepared by reacting the corresponding 1-free amino-alkylcyclohexane and the selected alpha, omega-dihaloalkyl compound, e.g., 1,3-dibromopropane, 1,4-dibromobutane, or 1,5-dibromopentane, according to the following representative example:

N-(1,3,3,5,5-pentamethylcyclohexyl)pyrrolidine hydrochloride

1,3,3,5,5-pentamethylcyclohexylamine hydrochloride (12 g, 58.3 mmol), potassium carbonate (48.4 g, 350 mmol) and 1,4-dibromobutane (7.32 ml, 61.3 mmol) were refluxed in acetonitrile (250 ml) for 60h. After cooling to r.t., the mixture was filtered and the precipitate was washed with diethyl ether (600 ml). The filtrate was concentrated in vacuo by rotary evaporation and the residue was fractionally distilled at reduced pressure (11mm/Hg). The fraction at 129°C was collected to obtain colorless oil (8.95 g). This was dissolved in diethyl ether (120 ml) and 2.7 M HCl solution in diethyl ether (30 ml) was added. The resulting precipitate was filtered off, washed with diethyl ether (3*30 ml) and dried in vacuo over NaOH to give N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine hydrochloride hydrate (12.9 g, 68%) with m.p. 158°C. PMR spectrum: (DMSO-d6, TMS) d: 0.97 (6H, s, 3,5-CH3); 1.11 (6H,s, 3,5-CH3); 0.8 - 1.4 (2H, cyclohexane 4-CH2) 1.41 (3H, s, 1-CH3); 1.69 (4H, m, cyclohexane 2,6-CH2); 1.84 (4H, m, pyrrolidine 3,4-CH2); 3.20 (4H, m, pyrrolidine 2,5-CH2); 10.9 ppm (1H, br s, NH+).

Elemental analysis (C15H29n*HCl*H2O) Found (%) C 65.0; H 11.7; N5.0 Calculated (%) C 64.8; H 11.6; N 5.0.

Electrophysiology

Hippocampi were obtained from rat embryos (E20 to E21) and were then transferred to Ca^{2+} and Mg^{2+} free Hank's buffered salt solution (Gibco) on ice. Cells were mechanically dissociated in 0.05% DNAase / 0.3% ovomucoid (Sigma) following an 8 minute pre-incubation with 0.66% trypsin / 0.1% DNAase (Sigma). The dissociated cells were then centrifuged at 18G for 10 minutes, re-suspended in minimum essential medium (Gibco) and plated at a density

of 150,000 cells cm^{-2} onto poly-DL-ornithine (Sigma) / laminin (Gibco) - precoated plastic Petri dishes (Falcon). The cells were nourished with $NaHCO_3$/HEPES-buffered minimum essential medium supplemented with 5% foetal calf serum and 5% horse serum (Gibco) and incubated at 37°C with 5%CO_2 at 95% humidity. The medium was exchanged completely following inhibition of further glial mitosis with cytosine-ß-D-arabinofuranoside (ARAC, 5 μM Sigma) after about 5 days *in vitro*.

Patch clamp recordings were made from these neurones after 15-21 days *in vitro* with polished glass electrodes (2–3 MΩ) in the whole cell mode at room temperature (20–22°C) with the aid of an EPC-7 amplifier (List). Test substances were applied using a modified fast application system (SF-77B Fast Step, Warner Instruments) with 100 μM opening diameter theta glass (Clark TGC 200-10) pulled with a Zeiss DMZ (Augsburg, Munich) horizontal puller. The contents of the intracellular solution were normally as follows (mM): CsCl (95), TEACl (20), EGTA (10), HEPES (10), $MgCl_2$ (1), $CaCl_2$ (0.2), glucose (10), Tris-ATP (5), Di-Tris-Phosphocreatinine (20), Creatine Phosphokinase (50 U); pH was adjusted to 7.3 with CsOH or HCl. The extracellular solutions had the following basic composition (mM): NaCl (140), KCl (3), $CaCl_2$ (0.2), glucose (10), HEPES (10), sucrose (4.5), tetrodotoxin (TTX $3*10^{-4}$).

N1E-115 cells were purchased from the European collection of cell cultures (ECACC, Salisbury, UK) and stored at -80°C until further use. The cells were plated at a density of 100,000 cells cm^{-2} onto plastic Petri dishes (Falcon) and were nourished with $NaHCO_3$/HEPES-buffered minimum essential medium (MEM) supplemented with 15% foetal calf serum (Gibco) and incubated at 37°C with 5%CO_2 at 95% humidity. The medium was exchanged completely

daily. Once every three days, cells were re-seeded onto fresh Petri dishes following treatment with trypsin-EDTA (1% in PBS), resuspension in MEM, and centrifugation at 1000 for 4 mins.

Patch clamp recordings were made from lifted cells, 2-3 days following seeding with polished glass electrodes (2–3 MΩ) in the whole cell mode at room temperature (20–22°C) with an EPC-7 amplifier (List). Test substances were applied as for hippocampal cells. The contents of the intracellular solution were as follows (mM): CsCl (130), HEPES (10), EGTA (10), $MgCl_2$ (2), $CaCl_2$ (2), K-ATP (2), Tris-GTP (0.2), D-Glucose (10); pH was adjusted to 7.3 with CsOH or HCl. The extracellular solutions had the following basic composition (mM): NaCl (124), KCl (2.8), HEPES (10), pH 7.3 with NaOH or HCl.

Only results from stable cells were accepted for inclusion in the final analysis, i.e., showing at least 75% recovery of responses to agonist (serotonin or Ach) following removal of the antagonist tested. Despite this, recovery from drug actions wasn't always 100% because of rundown in some cells (<= 10% over 10 mins). When present, this was always compensated by basing the % antagonism at each concentration on both control and recovery and assuming a linear time course for this rundown. All antagonists were assessed at steady-state blockade with 3 to 6 concentrations on at least 5 cells. Equilibrium blockade was achieved within 2 to 5 agonist applications, depending on antagonist concentration.

Results

Table 1 shows the general structure of selected amino-alkylcyclohexanes used in the present study.



Basic Structure of the Amino-alkylcyclohexanes

MRZ	R1	R2	R3	R4	R5	R*
579	CH_3	CH_3	CH_3	CH_3	CH_3	NH_2
601	CH_3	CH_3	CH_3	CH_3	C_3H_7	NH_2
607	CH_3	CH_3	H	CH_3	C_3H_7	NH_2
615	CH_3	CH_3	$C_2H_5(CH_3)$	$CH_3(C_2H_5)$	CH_3	NH_2
616	CH_3(H	H(CH_3	H(CH_3)	CH_3(H)	CH_3	NH_2
617	H	H	$CH_3(C_3H_7)$	$C_3H_7(CH_3)$	CH_3	NH_2
618	CH_3	H	C_3H_7	CH_3	CH_3	NH_2
620	H	H	$C_2H_5(CH_3)$	$CH_3(C_2H_5)$	CH_3	NH_2
621	H	H	CH_3	CH_3	CH_3	NH_2
625	H	H	H	CH_3	CH_3	NH_2
627	H	H	H	C_3H_7	CH_3	NH_2
629	H	H	H	C_2H_5	CH_3	NH_2
632	CH_3	CH_3	C_2H_5	H	CH_3	NH_2
633	CH_3	CH_3	H	C_2H_5	CH_3	NH_2
640	CH_3	CH_3	CH_3	CH_3	CH_3	$NHCH_3$
641	H	H	H	H	CH_3	NH_2
642	CH_3	CH_3	CH_3	CH_3	CH_3	$NH(CH_3)_2$
705	CH_3	CH_3	CH_3	CH_3	CH_3	$NH(CH_2)_4$

Table 1

Substitutions in brackets represent alternatives in racemic mixtures, e.g., $CH_3(C_3H_7)$ means CH_3 or C_3H_7.

* * * * *

BRIEF DESCRIPTION OF THE DRAWINGS:

FIG. 1A and FIG. 1B show concentration-dependence of the blockade of 5HT3 receptors by MRZ 2/633 in cultured N1E-115 cells. Serotonin (10µM) was applied for 2 seconds every 30 seconds in the continuous presence of various concentrations of MRZ 2/633 (1-10μM).

A: Original data for a single N1E-115 cell - serotonin was applied as indicated by the bars. The left and right panels show control and recovery responses respectively. The middle three panels show equilibrium responses in the continuous presence of MRZ 2/633 1, 3, and 10 μM respectively.

B: Peak and steady-state (plateau) serotonin current responses were normalized to control levels and plotted as means (±SEM) against MRZ 2/633 concentration (n=8). Estimation of IC_{50}s and curve fitting were made according to the 4 parameter logistic equation (GraFit, Erithacus Software).

FIG. 2A and FIG. 2B show that nicotine acts as a functional antagonist of neuronal nicotinic (type Ia = α7) receptors in hippocampal neurones by inducing receptor desensitization. Ach (1 mM) was applied for 2 seconds every 30 seconds in the continuous presence of various concentrations of (-) nicotine (1-10μM).

A: Original data for a single hippocampal neurone - Ach was applied as indicated by the bars. The left and right panels show control and recovery responses respectively. The middle three panels show equilibrium responses in the continuous presence of (-)nicotine 1, 3 and 10 μM respectively.

B: Peak ACh current responses were normalized to control levels and plotted as means (±SEM) against (-) nicotine concentration (n=12 per concentration). Estimation of IC_{50}s and curve fitting were made according

to the 4 parameter logistic equation (GraFit, Erithacus Software).

FIG. 3A and FIG. 3B show a concentration-dependence of the blockade of neuronal nicotinic (type Ia = α7) receptors by MRZ 2/616 in hippocampal neurones. Ach (1 mM) was applied for 2 seconds every 30 seconds in the continuous presence of various concentrations of MRZ 2/616 (1-100μM).

A: Original data for a single hippocampal neurone - Ach was applied as indicated by the bars. The left and right panels show control and recovery responses respectively. The middle three panels show equilibrium responses in the continuous presence of MRZ 2/616 10, 30 and 100 μM respectively

B: Peak ACh current responses were normalized to control levels and plotted as means (±SEM) against MRZ 2/616 concentration (n=11 per concentration). Estimation of IC_{50}s and curve fitting were made according to the 4 parameter logistic equation (GraFit, Erithacus Software).

FIG. 4A and FIG. 4B show concentration-dependence of the blockade of neuronal nicotinic (type Ia = α7) receptors by MRZ 2/705 in hippocampal neurones. Ach (1 mM) was applied for 2 seconds every 30 seconds in the continuous presence of various concentrations of MRZ 2/705 (0.3-30μM).

A: Original data for a single hippocampal neurone - Ach was applied as indicated by the bars. The left and right panels show control and recovery responses respectively. The middle three panels show equilibrium responses in the continuous presence of MRZ 2/705 0.3, 1.0 and 3.0 μM respectively

B: Peak ACh current responses were normalized to control levels and plotted as means (±SEM) against MRZ 2/705 concentration (n=9 per concentration). Estimation

of IC50s and curve fitting were made according to the 4 parameter logistic equation (GraFit, Erithacus Software).

* * * * *

Effects of amino-alkylcyclohexanes on 5-HT_3 receptors

All ten amino-alkylcyclohexanes tested antagonized serotonin-induced inward currents in N1E-115 cells with similar potencies to those previously reported for NMDA-induced inward currents (Fig. 1, see also Parsons et al., 1999). Similar effects were seen with the same compounds when tested on 5-HT_3 receptors permanently expressed in HEK-293 cells. As such, the amino-alkylcyclohexanes tested had similar effects on 5-HT_3 receptors as those previously reported for a variety of anti-depressants (Fan, 1994), i.e., they antagonized responses by inducing desensitization.

MRZ 2/	[^{3}H]MK-	PC NMDA	5HT$_3$
579	1.4	1.3	1.7
601	7.7	10.0	1.3
607	7.7	13.8	22.3
615	2.29	1.30	2.5
616	10.4	33.2	38.7
621	30.6	92.4	20.3
632	2.8	6.4	2.4
633	4.7	13.9	7.7
640	4.8	14.6	10.8
642	10.7	42.5	35.5

Table 2

Summary of the potencies of amino-alkylcyclohexanes on NMDA and 5-HT$_3$ receptors. Data for displacement of [^{3}H]MK-801 binding in rat cortical membranes and antagonism of NMDA-induced inward currents (at -70mV) in cultured rat hippocampal neurones are taken from Parsons et al., 1999. Potencies against 5-HT$_3$ receptors were assessed as IC$_{50}$s (μM) against "steady-state" responses of N1E-115 cells to serotonin (10μM) applied for 2 secs.

Effects of amino-alkylcyclohexanes on neuronal nicotinic receptors

Concentration-clamp application of Ach (1mM) to cultured hippocampal neurones elicited rapid, pronounced inward currents which rapidly desensitized to a much lower plateau level. Nicotine caused a concentration dependent block of neuronal responses to Ach and concentrations achieved in the CNS of smokers caused a substantial antagonism (Fig. 2, IC$_{50}$ = 1.17 μM).

We next accessed the potencies of a variety of amino-alkylcyclohexanes as α7 neuronal nicotinic antagonists. Simple amino-alkylcyclohexanes with low alkyl substitutions at positions R1 through R4 (see Table 1) were potent α7 neuronal nicotinic antagonists and some, as exemplified by MRZ 2/616 were actually much more potent in this regard than previously reported for NMDA receptors (see Fig. 3 and Parsons et al., 1999).

The N-pyrollidine derivative MRZ 2/705 was also 16 fold more effective as an α7 neuronal nicotinic antagonist than as an NMDA receptor antagonist (Table 3 and Fig. 4).

MRZ	[^{3}H]M	PC	PC Ach
579	1.44	1.30	30.00
615	2.29	2.90	2.21
616	9.94	33.20	3.40
617	36.08	63.90	1.16
618	22.79	57.50	0.65
620	24.18	99.00	2.44
621	30.56	92.40	0.65
625	48.98	244.90	3.29
627	67.30	150.00	2.60
629	46.74	218.60	2.05
641	135.86	>100	2.40
642	10.73	42.50	1.00
705	7.09	20.80	1.30

Table 3

Summary of the potencies of amino-alkylcyclohexanes on NMDA and α7 neuronal nicotinic receptors. Data for displacement of [^{3}H]MK-801 binding in rat cortical membranes and antagonism of NMDA-induced inward currents (at -70mV, PC NMDA) in cultured rat hippocampal neurones are taken from Parsons et al., 1999. Potencies against α7 neuronal nicotinic receptors (PC ACh) were assessed as IC_{50}s (μM) against peak responses of cultured hippocampal neurones to ACh (1 mM) applied for 2 secs.

Conclusions

The present data show that amino-alkylcyclohexanes are antagonists of 5-HT_3 receptors. These effects were seen at concentrations similar to, or even lower than, those required for uncompetitive antagonistic effects at NMDA receptors as reported by Parsons et al. 1999. Combined antagonistic effects of such compounds at NMDA and 5-HT_3 receptors will therefore lead to positive synergistic effects contributing to their therapeutic safety and efficacy in Alzheimer's disease by increasing desired effects - cognitive enhancement and

antidepressant effects - whilst further reducing possible negative effects of NMDA receptor antagonism by, e.g., reducing mesolimbic dopamine hyperactivity. Furthermore, 5-HT_3 antagonistic effects *per se* are useful in the treatment of cognitive deficits, depression, alcohol abuse, anxiety, migraine, irritable bowel syndrome, and emesis.

The present data show also that some amino-alkylcyclohexanes are in fact more potent as $\alpha 7$ neuronal nicotinic receptor antagonists than for actions at NMDA and/or 5-HT_3 receptors. It is likely that many of these agents are also antagonists of $\alpha 4 ß 2$ receptors, as already reported for agents like memantine and amantadine by Buisson et al. (1998). We propose that the positive effects reported by others for neuronal nicotinic agonists in animal models of various diseases are actually due to desensitization of $\alpha 7$ receptors and inactivation / down regulation of $\alpha 4/ß 2$ receptors or other forms of functional antagonism by, e.g., partial agonistic effects. Moderate concentrations of neuronal nicotinic receptor antagonists are therefore useful for neuroprotection against, or for the treatment of, disorders related to the malfunction of nicotinic transmission such as, e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, Tourette´s syndrome, drug abuse, and pain.

PHARMACEUTICAL COMPOSITIONS

The active ingredients of the invention, together with one or more conventional adjuvants, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as coated or uncoated tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules

filled with the same, all for oral use; in the form of suppositories or capsules for rectal administration or in the form of sterile injectable solutions for parenteral (including intravenous or subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional or new ingredients in conventional or special proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing twenty (20) to one hundred (100) milligrams of active ingredient or, more broadly, ten (10) to two hundred fifty (250) milligrams per tablet, are accordingly representative unit dosage forms.

METHOD OF TREATING

Due to their high degree of activity and their low toxicity, together presenting a most favorable therapeutic index, the active principles of the invention may be administered to a subject, e.g., a living animal (including a human) body, in need thereof, for the treatment, alleviation, or amelioration, palliation, or elimination of an indication or condition which is susceptible thereto, or representatively of an indication or condition set forth elsewhere in this application, preferably concurrently, simultaneously, or together with one or more pharmaceutically-acceptable excipients, carriers, or diluents, especially and preferably in the form of a pharmaceutical composition thereof, whether by oral, rectal, or parental (including intravenous and subcutaneous) or in some cases even topical route, in an effective amount. Dosage ranges may be 1-1000 milligrams daily, preferably 10-500 milligrams daily, and especially 50-500 milligrams daily, depending as usual upon the exact mode of administration, form in which administered,

the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.

EXAMPLES OF REPRESENTATIVE PHARMACEUTICAL COMPOSITIONS

With the aid of commonly used solvents, auxiliary agents and carriers, the reaction products can be processed into tablets, coated tablets, capsules, drip solutions, suppositories, injection and infusion preparations, and the like and can be therapeutically applied by the oral, rectal, parenteral, and additional routes. Representative pharmaceutical compositions follow.

(a) Tablets suitable for oral administration which contain the active ingredient may be prepared by conventional tabletting techniques.

(b) For suppositories, any usual suppository base may be employed for incorporation thereinto by usual procedure of the active ingredient, such as a polyethyleneglycol which is a solid at normal room temperature but which melts at or about body temperature.

(c) For parental (including intravenous and subcutaneous) sterile solutions, the active ingredient together with conventional ingredients in usual amounts are employed, such as for example sodium chloride and double-distilled water q.s., according to conventional procedure, such as filtration, aseptic filling into ampoules or IV-drip bottles, and autoclaving for sterility.

Other suitable pharmaceutical compositions will be immediately apparent to one skilled in the art.

The following examples are given by way of illustration only and are not to be construed as limiting.

EXAMPLE 1

Tablet Formulation

A suitable formulation for a tablet containing 10 milligrams of active ingredient is as follows:

	Mg.
Active Ingredient	10
Lactose	63
Microcrystalline Cellulose	21
Talcum	4
Magnesium stearate	1
Colloidal silicon dioxide	1

EXAMPLE 2

Tablet Formulation

Another suitable formulation for a tablet containing 100 mg is as follows:

	Mg.
Active Ingredient	100
Potato starch	20
Polyvinylpyrrolidone	10
Film coated and colored.	

The film coating material consists of:

Lactose	100
Microcryst. Cellulose	80
Gelatin	10
Polyvinylpyrrolidone, crosslinked	10
Talcum	10
Magnesium stearate	2
Colloidal silicon dioxide	3
Color pigments	5

EXAMPLE 3

Capsule Formulation

A suitable formulation for a capsule containing 50 milligrams of active ingredient is as follows:

	Mg.
Active Ingredient	50
Corn starch	20
Dibasic calcium phosphate	50
Talcum	2
Colloidal silicon dioxide	2

filled in a gelatin capsule.

EXAMPLE 4

Solution for injection

A suitable formulation for an injectable solution containing one percent of active ingredient is as follows:

Active Ingredient	mg	12
Sodium chloride	mg	8
Sterile water to make	ml	1

EXAMPLE 5

Liquid oral formulation

A suitable formulation for 1 liter of a liquid mixture containing 2 milligrams of active ingredient in one milliliter of the mixture is as follows:

	G.
Active Ingredient	2
Saccharose	250
Glucose	300
Sorbitol	150
Orange flavor	10
Sunset yellow.	
Purified water to make a total of 1000 ml.	

EXAMPLE 6

Liquid oral formulation

Another suitable formulation for 1 liter of a liquid mixture containing 20 milligrams of active ingredient in one milliliter of the mixture is as follows:

	G.
Active Ingredient	20
Tragacanth	7
Glycerol	50
Saccharose	400
Methylparaben	0.5
Propylparaben	0.05
Black currant-flavor	10
Soluble Red color	0.02
Purified water to make a total of 1000 ml.	

EXAMPLE 7

Liquid oral formulation

Another suitable formulation for 1 liter of a liquid mixture containing 2 milligrams of active ingredient in one milliliter of the mixture is as follows:

	G.
Active Ingredient	2
Saccharose	400
Bitter orange peel tincture	20
Sweet orange peel tincture	15
Purified water to make a total of 1000 ml.	

EXAMPLE 8

Aerosol formulation

180 g aerosol solution contain:

	G.
Active Ingredient	10
Oleic acid	5
Ethanol	81
Purified Water	9
Tetrafluoroethane	75

15 ml of the solution are filled into aluminum aerosol cans, capped with a dosing valve, purged with 3.0 bar.

EXAMPLE 9

TDS formulation

100 g solution contain:

	G.
Active Ingredient	10.0
Ethanol	57.5
Propyleneglycol	7.5
Dimethylsulfoxide	5.0
Hydroxyethylcellulose	0.4
Purified water	19.6

1.8 ml of the solution are placed on a fleece covered by an adhesive backing foil. The system is closed by a protective liner which will be removed before use.

EXAMPLE 10

Nanoparticle formulation

10 g of polybutylcyanoacrylate nanoparticles contain:

	G.
Active Ingredient	1.0
Poloxamer	0.1
Butylcyanoacrylate	8.75
Mannitol	0.1
Sodiumchloride	0.05

Polybutylcyanoacrylate nanoparticles are prepared by emulsion polymerization in a water/0.1 N HCl/ethanol mixture as polymerization medium. The nanoparticles in the suspension are finally lyophilized under vacuum.

The compounds of the invention thus find application in the treatment of disorders of a living animal body, especially a human, in both $5HT_3$ and nicotinic receptor

indications for both symptomatic and neuroprotective purposes

The method-of-treating a living animal body with a compound of the invention, for the inhibition of progression or alleviation of the selected ailment therein, is as previously stated by any normally-accepted pharmaceutical route, employing the selected dosage which is effective in the alleviation of the particular ailment desired to be alleviated.

Use of the compounds of the present invention in the manufacture of a medicament for the treatment of a living animal for inhibition of progression or alleviation of the selected ailment or condition, particularly ailments or conditions susceptible to treatment with a $5HT_3$ or nicotinic receptor antagonist, is carried out in the usual manner comprising the step of admixing an effective amount of a compound of the invention with a pharmaceutically-acceptable diluent, excipient, or carrier, and the method-of-treating, pharmaceutical compositions, and use of a compound of the present invention in the manufacture of a medicament are all in accord with the foregoing and with the disclosure of our prior USP 6,034,134 for the same 1-amino compounds, and representative acid addition salts, enantiomers, isomers, and hydrates, and their method of preparation is likewise disclosed in our prior USP and published WO application for the 1-amino-alkylcyclohexane compounds.

Representative pharmaceutical compositions prepared by admixing the active ingredient with a suitable pharmaceutically-acceptable excipient, diluent, or carrier, include tablets, capsules, solutions for injection, liquid oral formulations, aerosol formulations, TDS formulations, and nanoparticle formulations, thus to produce medicaments for oral,

injectable, or dermal use, also in accord with the foregoing and also in accord with examples of pharmaceutical compositions given in our U.S. patent 6,034,134 for these 1-amino-alkylcyclohexanes.

* * * * *

It is to be understood that the invention is not to be limited to the exact details of operation, or to the exact compositions, methods, procedures, or embodiments shown and described, as obvious modifications and equivalents will be apparent to one skilled in the art, and the invention is therefore to be limited only by the full scope which can be legally accorded to the appended claims.

REFERENCES

Buisson, B., Bertrand, D., 1998, Open-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptor. *Mol. Pharmacol.* 53, 555-563.

Fan, P., 1994, Effects of antidepressants on the inward current mediated by 5-HT_3 receptors in rat nodose ganglion neurones. Br J Pharmacol 112, 741-744.

Greenshaw, A.J., Silverstone, P.H., 1997, The non-antiemetic uses of serotonin 5-HT_3 receptor antagonists. Clinical pharmacology and therapeutic applications. Drugs 53, 20-39.

Parsons, C.G., Danysz, W., Bartmann, A., Spielmanns, P., Frankiewicz, T., Hesselink, M., Eilbacher, B., Quack, G., 1999, Amino-alkylcyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology 38, 85-108.

We claim:

A method-of-treating a living animal for inhibition of progression or alleviation of a condition which is alleviated by a $5HT_3$ or neuronal nicotinic receptor antagonist, comprising the step of administering to the said living animal an amount of a 1-aminoalkylcyclohexane compound selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein n+m = 0, 1, or 2

wherein R^1 through R^7 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C),

wherein R^8 and R^9 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C) or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, which is effective for the said purpose.

- 2 -

A method of Claim 1 wherein at least R^1, R^4, and R^5 are lower-alkyl.

- 3 -

A method of Claim 2 wherein R^1 through R^5 are methyl.

- 4 -

A method of Claim 1 wherein R^1 is ethyl.

- 5 -

A method of Claim 1 wherein R^2 is ethyl.

- 6 -

A method of Claim 1 wherein R^3 is ethyl.

- 7 -

A method of Claim 1 wherein R^4 is ethyl.

- 8 -

A method of Claim 1 wherein R^5 is ethyl.

- 9 -

A method of Claim 1 wherein R^5 is propyl.

- 10 -

A method of Claim 1 wherein R^6 or R^7 is methyl.

- 11 -

A method of Claim 1 wherein R^6 or R^7 is ethyl.

- 12 -

A method of Claim 2 wherein X is 4 or 5.

- 13 -

A method of Claim 3 wherein X is 4 or 5.

- 14 -

A method of Claim 1 wherein the condition treated or inhibited is selected from the group consisting of emesis, anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease, cerebella tremor, Parkinson's disease, Tourette's, pain, and appetite disorders.

- 15 -

A method of Claim 1 wherein the compound is selected from the group consisting of

1-Amino-1,3,3,5,5-pentamethylcyclohexane,

1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane,

1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group),

1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers),

1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers),

1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers),

1-Amino-1,3 (trans),5 (trans)-trimethyl-3(cis)-propylcyclohexane,

1-Amino-1,3-dimethyl-3-ethylcyclohexane,

1-Amino-1,3,3-trimethylcyclohexane,

1-Amino-1,3 (trans)-dimethylcyclohexane,

1-Amino-1-methyl-3 (trans) propylcyclohexane,

1-Amino-1-methyl-3 (trans) ethylcyclohexane,

1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane,

1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane,

N-methyl-1-Amino-1,3,3,5.5-pentamethylcyclohexane,

1-Amino-1-methylcyclohexane,

N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,

1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane,

1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,

1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,

1-Amino-1-methyl-3(cis)-methyl-cyclohexane,

1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and

N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,

and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts of any of the foregoing.

- 16 -

A method of Claim 1 wherein the compound is administered in the form of a pharmaceutical composition thereof comprising the compound in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.

- 17 -

A method of Claim 15 wherein the compound is administered in the form of a pharmaceutical composition thereof comprising the compound in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.

Use of a 1-aminoalkylcyclohexane selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein n+m = 0, 1, or 2

wherein R^1 through R^7 are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C), wherein R^8 and R^9 are independently selected from the group consisting of hydrogen and lower-alkyl or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, in the manufacture of a medicament to treat a living animal for inhibition of progression or alleviation of a condition which is alleviated by a $5HT_3$ or neuronal nicotinic receptor antagonist.

Use of Claim 18 wherein at least R^1, R^4, and R^5 are lower-alkyl.

Use of Claim 19 wherein R^1 through R^5 are methyl.

- 21 -

Use of Claim 18 wherein x is 4 or 5.

- 22 -

Use of Claim 19 wherein x is 4 or 5.

- 23 -

Use of Claim 18 wherein the compound is selected from the group consisting of

1-Amino-1,3,3,5,5-pentamethylcyclohexane,

1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane,

1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group),

1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers),

1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers),

1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers),

1-Amino-1,3 (trans),5 (trans)-trimethyl-3(cis)-propylcyclohexane,

1-Amino-1,3-dimethyl-3-ethylcyclohexane,

1-Amino-1,3,3-trimethylcyclohexane,

1-Amino-1,3 (trans)-dimethylcyclohexane,

1-Amino-1-methyl-3 (trans) propylcyclohexane,

1-Amino-1-methyl-3 (trans) ethylcyclohexane,

1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane,

1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane,

N-methyl-1-Amino-1,3,3,5.5-pentamethylcyclohexane,

1-Amino-1-methylcyclohexane,

N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,

1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane,

1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,

1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,

1-Amino-1-methyl-3(cis)-methyl-cyclohexane,

1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and

N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,

and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts of any of the foregoing.

- 24 -

Use of claim 18 wherein the condition treated or inhibited is selected from the group consisting of emesis, anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease, cerebella tremor, Parkinson's disease, Tourette's, pain, and appetite disorders.

ABSTRACT OF THE DISCLOSURE

Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist.





Patch clamp recordings from cultured hippocampal neurons

FIG 1





FIG 2





FIG 3



FIG 4

MERZ30/dln

DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name, and

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled

AMINO-ALKYLCYCLOHEXANES AS 5-HT_3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS

the specification of which is attached hereto.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

We hereby appoint the following person registered to practice before the Patent and Trademark Office as our attorney with full power of substitution and revocation to prosecute this application and all divisions and continuations thereof and to transact all business in the Patent and Trademark Office connected therewith and request that all correspondence be sent to him at the mailing address hereafter given:

Name	GORDON W. HUESCHEN
Registration No.	16,157
Name	G. Patrick Sage
Registration No.	37,710
Address	The Firm of Gordon W. Hueschen 715 The "H" Building 310 East Michigan Avenue Kalamazoo, MI 49007

I further request that all telephone communications be directed to:

Name	GORDON W. HUESCHEN
Telephone No.	616-382-0030

First Inventor's Signature _____ Date June 8 2000

Full name of first inventor Christopher Graham Raphael Parsons

Residence Nidderau, Germany Citizenship British
Post Office Address Wartbaumstrasse 38
D-61130 Nidderau
Germany

Second Inventor's Signature _____ Date June 8, 2000
Full name of second inventor Wojciech Danysz
Residence Nidderau, Germany Citizenship Polish
Post Office Address Vor den Gärten 16
D-61130 Nidderau
Germany

Third Inventor's Signature _____ Date June 8, 2000
Full name of third inventor Markus Gold

Residence Nauheim, Germany Citizenship German
Post Office Address Kranichstrasse 9
6085 Nauheim
Germany

Fourth Inventor's Signature _____ Date June 8, 2000
Full name of fourth inventor Ivars Kalvinsh

Residence Salaspils, Latvia Citizenship Latvian
Post Office Address Miera 17-8
LV-2169 Salaspils
Latvia

Fifth Inventor's Signature _____ Date June 8, 2000
Full name of fifth inventor Valerjans Kauss

Residence Riga, Latvia Citizenship Latvian
Post Office Address A. Deglava 108/2-36
Riga LV 1082
Latvia

Sixth Inventor's Signature _____ Date June 8, 2000
Full name of sixth inventor Aigars Jirgensons

Residence Riga, Lativa Citizenship Latvian
Post Office Address Basteja Bulv. 10-48
Riga LV 1050
Latvia